Mirabegron
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Mirabegron |
| DrugBank ID | DB08893 |
| Brand Names (EU) | Betmiga |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 93.25% |
Approved Indication (EMA)
Overactive bladder in adults Betmiga prolonged-release tablets are indicated for symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome. Neurogenic detrusor overactivity in the paediatric population Betmiga prolonged release tablets are indicated for treatment of neurogenic detrusor overactivity (NDO) in paediatric patients aged 3 to less than 18 years.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | overactive bladder (disease) | 93.25% | DL |
| 2 | thoracic malformation | 83.06% | DL |
| 3 | renal-hepatic-pancreatic dysplasia | 82.93% | DL |
| 4 | polycystic kidney disease 3 with or without polycystic liver disease | 82.20% | DL |
| 5 | Joubert syndrome with renal defect | 80.89% | DL |
| 6 | adult familial nephronophthisis-spastic quadriparesia syndrome | 80.32% | DL |
| 7 | esophageal varices without bleeding | 80.05% | DL |
| 8 | esophageal varices with bleeding | 80.05% | DL |
| 9 | hypotrichosis simplex of the scalp | 79.47% | DL |
| 10 | karyomegalic interstitial nephritis | 79.24% | DL |
| 11 | congenital hypotrichosis milia | 77.54% | DL |
| 12 | 16q24.1 microdeletion syndrome | 75.15% | DL |
| 13 | primary interstitial lung disease specific to childhood | 74.17% | DL |
| 14 | isolated pulmonary capillaritis | 73.40% | DL |
| 15 | low compliance bladder | 73.23% | DL |
| 16 | diffuse alopecia areata | 71.42% | DL |
| 17 | congenital pulmonary lymphangiectasia | 67.75% | DL |
| 18 | polycystic kidney disease | 66.72% | DL |
| 19 | varicose disease | 64.28% | DL |
| 20 | autosomal ichthyosis syndrome with fatal disease course | 63.51% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.